← All trials
NCT06432296
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 20, 2024
- Primary completion
- Aug 3, 2025
- Completion date
- Nov 11, 2025
- First posted
- May 29, 2024
- Last posted
- May 29, 2024
- Enrollment
- 270
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Wuhan YZY Biopharma Co., Ltd.Lead sponsor
- Harbin Medical UniversityOfficial
- People's Liberation Army of ChinaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.